CN119390841A - 用于调节β链介导的免疫的组合物和方法 - Google Patents

用于调节β链介导的免疫的组合物和方法 Download PDF

Info

Publication number
CN119390841A
CN119390841A CN202411513821.5A CN202411513821A CN119390841A CN 119390841 A CN119390841 A CN 119390841A CN 202411513821 A CN202411513821 A CN 202411513821A CN 119390841 A CN119390841 A CN 119390841A
Authority
CN
China
Prior art keywords
antibody
amino acid
cdr2
cdr3
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411513821.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·加内桑
I·S·格鲁沃尔
S·辛格
M·R·汉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority claimed from CN202280086558.9A external-priority patent/CN118488966A/zh
Publication of CN119390841A publication Critical patent/CN119390841A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202411513821.5A 2021-11-01 2022-11-01 用于调节β链介导的免疫的组合物和方法 Pending CN119390841A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202163274446P 2021-11-01 2021-11-01
US202163274449P 2021-11-01 2021-11-01
US202163274430P 2021-11-01 2021-11-01
US63/274449 2021-11-01
US63/274446 2021-11-01
US63/274430 2021-11-01
CN202280086558.9A CN118488966A (zh) 2021-11-01 2022-11-01 用于调节β链介导的免疫的组合物和方法
PCT/US2022/079051 WO2023077155A1 (en) 2021-11-01 2022-11-01 Compositions and methods for the modulation of beta chain-mediated immunity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280086558.9A Division CN118488966A (zh) 2021-11-01 2022-11-01 用于调节β链介导的免疫的组合物和方法

Publications (1)

Publication Number Publication Date
CN119390841A true CN119390841A (zh) 2025-02-07

Family

ID=84364285

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411513821.5A Pending CN119390841A (zh) 2021-11-01 2022-11-01 用于调节β链介导的免疫的组合物和方法

Country Status (10)

Country Link
US (1) US20250092134A1 (enExample)
EP (2) EP4426734A1 (enExample)
JP (1) JP2024543019A (enExample)
KR (1) KR20240099397A (enExample)
CN (1) CN119390841A (enExample)
AU (1) AU2022377084A1 (enExample)
CA (1) CA3237038A1 (enExample)
IL (1) IL312464A (enExample)
MX (1) MX2024005336A (enExample)
WO (1) WO2023077155A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
CN119954959A (zh) * 2019-03-11 2025-05-09 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体

Also Published As

Publication number Publication date
AU2022377084A1 (en) 2024-06-20
EP4426734A1 (en) 2024-09-11
IL312464A (en) 2024-06-01
MX2024005336A (es) 2024-07-22
JP2024543019A (ja) 2024-11-19
EP4524160A2 (en) 2025-03-19
EP4524160A3 (en) 2025-09-24
WO2023077155A1 (en) 2023-05-04
CA3237038A1 (en) 2023-05-04
US20250092134A1 (en) 2025-03-20
KR20240099397A (ko) 2024-06-28

Similar Documents

Publication Publication Date Title
CN113966231B (zh) 用于调节t细胞介导的免疫力的材料和方法
US12076413B2 (en) Compositions and methods for modulating delta gamma chain mediated immunity
CN116635052A (zh) 用于调节分化簇iv和/或viii的生物工程t细胞介导的免疫、材料和其他方法
US12037391B2 (en) Anti-DLL3 antibodies and uses thereof
US20220127359A1 (en) Anti-vbeta17/anti-cd123 bispecific antibodies
US12448449B2 (en) Immune targeting molecules and uses thereof
CN115605512A (zh) 用于调节δ链介导的免疫的材料和方法
JP2024505673A (ja) 電荷対を有する二重特異性抗体及びその使用
EP4524160A2 (en) Compositions and methods for the modulation of beta chain-mediated immunity
CN118488966A (zh) 用于调节β链介导的免疫的组合物和方法
CN116615456A (zh) 用于调节β链介导的免疫的方法和组合物
WO2025221736A2 (en) Ltbr binding molecules and uses thereof
HK40110312A (en) Anti-dll3 antibodies and uses thereof
HK40039992A (en) Anti-dll3 antibodies and uses thereof
HK40039992B (en) Anti-dll3 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination